Edward B Kaczmarski
Overview
Explore the profile of Edward B Kaczmarski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
815
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McHugh M, Gray S, Kaczmarski E, Guiver M
J Med Microbiol
. 2015 Aug;
64(11):1321-1328.
PMID: 26253287
Since 1996 the Meningococcal Reference Unit (MRU) in Manchester has provided a national service for PCR confirmation of meningococcal and pneumococcal disease. Neisseria meningitidis serogroup B is predominant in the...
2.
Bidmos F, Chan H, Praekelt U, Tauseef I, Ali Y, Kaczmarski E, et al.
PLoS One
. 2015 Jul;
10(7):e0133855.
PMID: 26208277
Acquisition of iron from host complexes is mediated by four surface-located receptors of Neisseria meningitidis. The HmbR protein and heterodimeric HpuAB complex bind to haemoglobin whilst TbpBA and LbpBA bind...
3.
Lucidarme J, Findlow J, Chan H, Feavers I, Gray S, Kaczmarski E, et al.
PLoS One
. 2013 Oct;
8(9):e76932.
PMID: 24098814
Two haemoglobin-binding proteins, HmbR and HpuAB, contribute to iron acquisition by Neisseria meningitidis. These receptors are subject to high frequency, reversible switches in gene expression--phase variation (PV)--due to mutations in...
4.
Lucidarme J, Gilchrist S, Newbold L, Gray S, Kaczmarski E, Richardson L, et al.
Clin Vaccine Immunol
. 2013 Jun;
20(9):1360-9.
PMID: 23803905
The poor immunogenicity of the meningococcal serogroup B (MenB) capsule has led to the development of vaccines targeting subcapsular antigens, in particular the immunodominant and diverse outer membrane porin, PorA....
5.
Ladhani S, Flood J, Ramsay M, Campbell H, Gray S, Kaczmarski E, et al.
Vaccine
. 2012 Mar;
30(24):3710-6.
PMID: 22429756
A number of meningococcal vaccines have either been recently licensed or are in late-phase clinical trials. To inform national vaccination policy, it is important to define the burden of disease...
6.
Ladhani S, Lucidarme J, Newbold L, Gray S, Carr A, Findlow J, et al.
Emerg Infect Dis
. 2012 Jan;
18(1):63-70.
PMID: 22261040
Enhanced national surveillance for invasive meningococcal disease in England and Wales identified an increase in laboratory-confirmed capsular group Y (MenY) disease from 34 cases in 2007 to 44 in 2008...
7.
Darton T, Guiver M, Naylor S, Kaczmarski E, Borrow R, Read R
Clin Infect Dis
. 2011 Jul;
53(5):463-7.
PMID: 21798855
Among 384 patients with confirmed meningococcal disease, the likelihood of detecting Neisseria meningitidis DNA in cerebrospinal fluid (CSF) increased with age, serogroup B infection, and prehospitalization antibiotic treatment. Plasma and...
8.
Lucidarme J, Newbold L, Findlow J, Gilchrist S, Gray S, Carr A, et al.
Clin Vaccine Immunol
. 2010 Dec;
18(2):194-202.
PMID: 21123522
In 2007, recommendations were proposed for the molecular typing of meningococci. Multilocus sequence typing (MLST) was recommended to guide national and international disease management and facilitate studies of population biology...
9.
Lucidarme J, Comanducci M, Findlow J, Gray S, Kaczmarski E, Guiver M, et al.
Clin Vaccine Immunol
. 2010 Apr;
17(6):919-29.
PMID: 20375242
Invasive disease caused by meningococcal capsular groups A, C, W-135, and Y is now preventable by means of glycoconjugate vaccines that target their respective polysaccharide capsules. The capsule of group...
10.
Lucidarme J, Comanducci M, Findlow J, Gray S, Kaczmarski E, Guiver M, et al.
J Clin Microbiol
. 2009 Sep;
47(11):3577-85.
PMID: 19759227
Highly effective glycoconjugate vaccines exist against four of the five major pathogenic groups of meningococci: A, C, W-135, and Y. An equivalent vaccine against group B meningococci (menB) has remained...